Topoisomerase-targeting antitumor drugs
- 1 December 1989
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 989 (2), 163-177
- https://doi.org/10.1016/0304-419x(89)90041-3
Abstract
No abstract availableKeywords
This publication has 80 references indexed in Scilit:
- Effect of genistein on topoisomerase activity and on the growth of [VAL 12]Ha-ras-transformed NIH 3T3 cellsBiochemical and Biophysical Research Communications, 1988
- Mitotic recombination in the rDNA of S. cerevisiae is suppressed by the combined action of DNA topoisomerases I and IICell, 1988
- Cell cycle stage-dependent variations in drug-induced topoisomerase II mediated DNA cleavage and cytotoxicityBiochemistry, 1987
- The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4′-(9-acridinylamino) methanesulfon-m-anisidide (m-AMSA) or 4-(4,6-0-ethylidene-β-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells to the drugsBiochemical and Biophysical Research Communications, 1987
- Isolation of intercalator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase IIBiochemistry, 1986
- In vivo mapping of DNA topoisomerase II-specific cleavage sites on SV40 chromatinCell, 1985
- Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationshipBiochemistry, 1984
- Tumor Promoter TPA Mimics Irradiation Effects on the Cell Cycle of HeLa CellsScience, 1980
- Intracellular degradation of HeLa and adenovirus type 2 DNA induced by camptothecinBiochemical and Biophysical Research Communications, 1971
- 4′-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of actionEuropean Journal of Cancer (1965), 1970